{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:24:37Z","timestamp":1784168677405,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T00:00:00Z","timestamp":1353283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T00:00:00Z","timestamp":1353283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/bmt.2012.218","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T13:31:31Z","timestamp":1353331891000},"page":"646-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant"],"prefix":"10.1038","volume":"48","author":[{"given":"T L","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S E","family":"Seropian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Bolognia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,19]]},"reference":[{"key":"BFbmt2012218_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","volume":"14","author":"BS Andersson","year":"2008","unstructured":"Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS. Biol Blood Marrow Transplant 2008; 14: 672\u2013684.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012218_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.bbmt.2008.06.009","volume":"14","author":"CN Bredeson","year":"2008","unstructured":"Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 993\u20131003.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012218_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/bmt.2008.13","volume":"41","author":"S Chunduri","year":"2008","unstructured":"Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH et al. Fludarabine\/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant 2008; 41: 935\u2013940.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012218_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","volume":"104","author":"M de Lima","year":"2004","unstructured":"de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857\u2013864.","journal-title":"Blood"},{"key":"BFbmt2012218_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","volume":"8","author":"JA Russell","year":"2002","unstructured":"Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468\u2013476.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012218_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.bbmt.2009.11.017","volume":"16","author":"JA Russell","year":"2010","unstructured":"Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant 2010; 16: 509\u2013514.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012218_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00277-003-0654-9","volume":"82","author":"N Kr\u00f6ger","year":"2003","unstructured":"Kr\u00f6ger N, Bornh\u00e4user M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine\/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336\u2013342.","journal-title":"Ann Hematol"},{"key":"BFbmt2012218_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.bbmt.2011.02.011","volume":"17","author":"S Santarone","year":"2011","unstructured":"Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E et al. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Transplant 2011; 17: 1505\u20131511.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012218_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3109\/10428194.2010.529205","volume":"52","author":"FR Kerbauy","year":"2011","unstructured":"Kerbauy FR, Rodrigues M, de Souza Santos FP, Sobrinho JN, Kutner JM, Torres MA et al. Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning. Leuk Lymphoma 2011; 52: 321\u2013324.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2012218_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","volume":"14","author":"M Geddes","year":"2008","unstructured":"Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220\u2013228.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012218_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/hon.985","volume":"29","author":"M Hamadani","year":"2011","unstructured":"Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A et al. Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematol Oncol 2011; 29: 202\u2013210.","journal-title":"Hematol Oncol"},{"key":"BFbmt2012218_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1756-8722-3-36","volume":"3","author":"J Pidala","year":"2010","unstructured":"Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010; 3: 36.","journal-title":"J Hematol Oncol"},{"key":"BFbmt2012218_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bbmt.2007.06.005","volume":"13","author":"SG Ryu","year":"2007","unstructured":"Ryu SG, Lee JH, Choi SJ, Lee YS, Seol M, Hur EH et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1095\u20131105.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012218_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bbmt.2008.05.010","volume":"14","author":"JA Russell","year":"2008","unstructured":"Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR et al. Transplantation from matched siblings using once-daily intravenous busulfan\/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008; 14: 888\u2013895.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2012218_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","volume":"59","author":"JL Bolognia","year":"2008","unstructured":"Bolognia JL, Cooper DL, Glusac EJ . Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59: 524\u2013529.","journal-title":"J Am Acad Dermatol"},{"key":"BFbmt2012218_CR16","first-page":"646","volume":"33","author":"H Ikeda","year":"1999","unstructured":"Ikeda H, Kawano H, Kitaura T, Kimura A, Kihira K . Acral erythema associated with high-dose methotrexate infusion. Ann Pharmacother 1999; 33: 646.","journal-title":"Ann Pharmacother"},{"key":"BFbmt2012218_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/archderm.1996.03890290132023","volume":"132","author":"I Hellier","year":"1996","unstructured":"Hellier I, Bessis D, Sotto A, Margueritte G, Guilhou JJ . High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996; 132: 590\u2013591.","journal-title":"Arch Dermatol"},{"key":"BFbmt2012218_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D33SH231VV","volume":"9","author":"V Feizy","year":"2003","unstructured":"Feizy V, Namazi MR, Barikbin B, Ehsani A . Methotrexate-induced acral erythema with bullous reaction. Dermatol Online J 2003; 9: 14.","journal-title":"Dermatol Online J"},{"key":"BFbmt2012218_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/bmt.2009.133","volume":"45","author":"R Beri","year":"2010","unstructured":"Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010; 45: 249\u2013253.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2012218_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2141.1991.tb08621.x","volume":"77","author":"M Morgan","year":"1991","unstructured":"Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J . The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77: 529\u2013534.","journal-title":"Br J Haematol"},{"key":"BFbmt2012218_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00148581-200709040-00008","volume":"9","author":"SM Hoy","year":"2007","unstructured":"Hoy SM, Lyseng-Williamson KA . Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs 2007; 9: 271\u2013278.","journal-title":"Paediatr Drugs"},{"key":"BFbmt2012218_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1001\/archderm.1986.01660210073021","volume":"122","author":"MK Crider","year":"1986","unstructured":"Crider MK, Jansen J, Norins AL, McHale MS . Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 1986; 122: 1023\u20131027.","journal-title":"Arch Dermatol"},{"key":"BFbmt2012218_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1046\/j.1365-2230.1999.00419.x","volume":"24","author":"RM Azurdia","year":"1999","unstructured":"Azurdia RM, Clark RE, Friedmann PS . Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999; 24: 64\u201366.","journal-title":"Clin Exp Dermatol"},{"key":"BFbmt2012218_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7326\/0003-4819-97-1-61","volume":"97","author":"WH Burgdorf","year":"1982","unstructured":"Burgdorf WH, Gilmore WA, Ganick RG . Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982; 97: 61\u201362.","journal-title":"Ann Intern Med"},{"key":"BFbmt2012218_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archderm.1985.01660010106031","volume":"121","author":"LE Levine","year":"1985","unstructured":"Levine LE, Medenica MM, Lorincz AL, Soltani K, Raab B, Ma A . Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 1985; 121: 102\u2013104.","journal-title":"Arch Dermatol"},{"key":"BFbmt2012218_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","volume":"101","author":"JJ Lokich","year":"1984","unstructured":"Lokich JJ, Moore C . Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798\u2013799.","journal-title":"Ann Intern Med"},{"key":"BFbmt2012218_CR27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2011.12.584","volume":"18","author":"JB Perkins","year":"2012","unstructured":"Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1099\u20131107.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2012218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2012218","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2012218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:13:19Z","timestamp":1648048399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2012218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,19]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["BFbmt2012218"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2012.218","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,19]]},"assertion":[{"value":"29 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}